Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 6Phase 3 4Phase 1 3

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 138Carcinoma, Non-Small-Cell Lung 109Prostatic Neoplasms 51Lung Neoplasms 31Neoplasm Metastasis 20Stomach Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Nasopharyngeal Carcinoma 16Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Esophageal Neoplasms 11Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7HER2-positive Breast Cancer 7Esophageal Squamous Cell Carcinoma 7Ovarian Neoplasms 6Carcinoma 6Adenocarcinoma 6Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma of Lung 5Triple Negative Breast Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Adenocarcinoma Of Esophagus 4Primary Breast Cancer 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Gemcitabine 12Mitomycin 11Cisplatin 10Carboplatin 8pembrolizumab 7Docetaxel 4toripalimab 3avelumab 3atezolizumab 3Paclitaxel 3sacituzumab govitecan 2disitamab vedotin 2Taxes 2Specimen Handling 2Platinum 2Magnetic Resonance Spectroscopy 2Injections 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1valrubicin 1tislelizumab 1lenvatinib 1eribulin 1epacadostat 1enfortumab vedotin 1durvalumab 1dodecyl maltoside 1Vitamin B 12 1Standard of Care 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Transitional Cell × Docetaxel × Clear all
NCT06524544 2026-05-27

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
320 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
184 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06857175 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
508 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT02426125 2023-08-21

RANGE

Eli Lilly and Company

Phase 3 Completed
530 enrolled 22 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡